



Bundesanstalt für Arbeitsschutz  
und Arbeitsmedizin  
Federal Institute for Occupational  
Safety and Health

## Justification Document for the Selection of a CoRAP Substance

**Substance Name (public name):** 2-ethylhexyl salicylate

**EC Number:** 204-263-4

**CAS Number:** 118-60-5

**Authority:** German CA

**Date:** 20/03/2018

### Cover Note

This document has been prepared by the evaluating Member State  
given in the CoRAP update.

## Table of Contents

<b>1</b>	<b>IDENTITY OF THE SUBSTANCE</b>	<b>3</b>
1.1	Other identifiers of the substance	3
1.2	Similar substances/grouping possibilities	3
<b>2</b>	<b>OVERVIEW OF OTHER PROCESSES / EU LEGISLATION</b>	<b>8</b>
<b>3</b>	<b>HAZARD INFORMATION (INCLUDING CLASSIFICATION)</b>	<b>9</b>
3.1	Classification	9
3.1.1	Harmonised Classification in Annex VI of the CLP	9
3.1.2	Self classification	9
3.1.3	Proposal for Harmonised Classification in Annex VI of the CLP	9
<b>4</b>	<b>INFORMATION ON (AGGREGATED) TONNAGE AND USES</b>	<b>10</b>
4.1	Tonnage and registration status	10
4.2	Overview of uses	10
<b>5.</b>	<b>JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE</b>	<b>11</b>
5.1.	Legal basis for the proposal	11
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)	11
5.3.	Initial grounds for concern to be clarified under Substance Evaluation	11
5.4.	Preliminary indication of information that may need to be requested to clarify the concern	12
5.5.	Potential follow-up and link to risk management	12

## 1 IDENTITY OF THE SUBSTANCE


### 1.1 Other identifiers of the substance

Table: Other Substance identifiers

<b>EC name (public):</b>	2-ethylhexyl salicylate
<b>IUPAC name (public):</b>	2-ethylhexyl salicylate
<b>Index number in Annex VI of the CLP Regulation:</b>	N/A
<b>Molecular formula:</b>	C <sub>15</sub> H <sub>22</sub> O <sub>3</sub>
<b>Molecular weight or molecular weight range:</b>	250.33 g/mol
<b>Synonyms:</b>	2-ethylhexyl 2-hydroxybenzoate 2-Ethylhexylsalicylate Ethylhexyl Salicylate p-menth-1-en-8-ol SOCT Sunobel® OS

**Type of substance**     Mono-constituent     Multi-constituent     UVCB


**Structural formula:**



### 1.2 Similar substances/grouping possibilities


The group of salicylates (i.e. esters of 2-hydroxysalicylate as indicated below) can be considered as similar.

**Structural formula:**



**Table 2: Similar substance**


<b>EC number:</b>	204-262-9
<b>EC name (public):</b>	benzyl salicylate
<b>CAS number:</b>	118-60-1
<b>IUPAC name (public):</b>	benzyl salicylate
<b>Index number in Annex VI of the CLP Regulation:</b>	
<b>Molecular formula:</b>	C <sub>14</sub> H <sub>12</sub> O <sub>3</sub>
<b>Molecular weight or molecular weight range:</b>	228.24 g/mol
<b>Synonyms:</b>	<i>2-hydroxybenzoic acid phenylmethyl ester</i> <i>Benzoic acid, 2-hydroxy-, phenylmethyl ester</i> <i>Benzyl 2-hydroxybenzoate</i> <i>Benzyl-2 hydroxibensoate</i> <i>Benzylsalicylat</i> <i>Phenylmethyl 2-hydroxybenzoate</i> <i>Salicylic acid, benzylester</i> <i>Benzyl o-hydroxybenzoate</i> <i>Phenylmethyl 2-hydroxybenzoate</i> <i>Salicylic acid, benzyl ester</i>

**Structural formula:**

Benzyl salicylate is proposed for substance evaluation in parallel to 2-ethylhexyl salicylate due to their structural similarity.

**Table 3: Similar substance**

<b>EC number:</b>	204-260-8
<b>EC name (public):</b>	Homosalate
<b>CAS number:</b>	118-56-9
<b>IUPAC name (public):</b>	3,3,5-trimethylcyclohexyl salicylate
<b>Index number in Annex VI of the CLP Regulation:</b>	n.a.
<b>Molecular formula:</b>	C <sub>16</sub> H <sub>22</sub> O <sub>3</sub>
<b>Molecular weight or molecular weight range:</b>	262,34 g/mol
<b>Synonyms:</b>	<i>(3,3,5-trimethylcyclohexyl) 2-hydroxybenzoate</i> <i>Homomenthylsalicylate</i> <i>Sunobel®HMS</i>


**Structural formula:**

The substance has been included in the Public Activity Coordination Tool (PACT) due to an RMOA process initiated by France.<sup>1</sup>

<sup>1</sup> PACT section on homosalate: [https://echa.europa.eu/de/addressing-chemicals-of-concern/substances-of-potential-concern/pact/-/substance-rev/12933/term?\\_viewsubstances\\_WAR\\_echarevsubstanceportlet\\_SEARCH\\_CRITERIA\\_EC\\_NUMBER=204-260-8](https://echa.europa.eu/de/addressing-chemicals-of-concern/substances-of-potential-concern/pact/-/substance-rev/12933/term?_viewsubstances_WAR_echarevsubstanceportlet_SEARCH_CRITERIA_EC_NUMBER=204-260-8)

**Table 4: Similar substance**

<b>EC number:</b>	228-408-6
<b>EC name (public):</b>	hexyl salicylate
<b>CAS number:</b>	6259-76-3
<b>IUPAC name (public):</b>	hexyl salicylate
<b>Index number in Annex VI of the CLP Regulation:</b>	n.a.
<b>Molecular formula:</b>	C <sub>13</sub> H <sub>18</sub> O <sub>3</sub>
<b>Molecular weight or molecular weight range:</b>	222.282 g/mol
<b>Synonyms:</b>	<i>Benzoic acid, 2-hydroxy-, hexyl ester Hexyl Salicylate Hexyl o-hydroxybenzoaten-Hexyl Salicylate</i>


**Structural formula:**

The substance has been subjected to REACH substance evaluation by the Netherlands in 2012.<sup>2</sup>

<sup>2</sup> CoRAP section on hexyl salicylate: <https://echa.europa.eu/de/information-on-chemicals/evaluation/community-rolling-action-plan/corap-table/-/dislist/details/0b0236e1807e3d24>

**Table 5: Similar substance**

<b>EC number:</b>	204-317-7
<b>EC name (public):</b>	methyl salicylate
<b>CAS number:</b>	119-36-8
<b>IUPAC name (public):</b>	methyl salicylate
<b>Index number in Annex VI of the CLP Regulation:</b>	n.a.
<b>Molecular formula:</b>	C <sub>8</sub> H <sub>8</sub> O <sub>3</sub>
<b>Molecular weight or molecular weight range:</b>	152.1482 g/mol
<b>Synonyms:</b>	<i>methyl 2-hydroxybenzoate</i> <i>Methyl 2-hydroxybenzoate</i> <i>METHYL SALICYLATE</i> <i>methyl-2-hydroxybenzoate</i> <i>METHYL-SALICYLATE</i> <i>Metil szalicilát</i> <i>salicylic acid, methyl ester</i>

**Structural formula:**

The substance has been subjected to REACH substance evaluation by France in 2015.<sup>3</sup>

<sup>3</sup> CoRAP section on methyl salicylate: <https://echa.europa.eu/de/information-on-chemicals/evaluation/community-rolling-action-plan/corap-table/-/dislist/details/0b0236e1807e9072>

## 2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

**Table: Completed or ongoing processes**

RMOA	<input type="checkbox"/> Risk Management Option Analysis (RMOA)	
REACH Processes	Evaluation	<input type="checkbox"/> Compliance check, Final decision
		<input checked="" type="checkbox"/> Testing proposal
		<input type="checkbox"/> CoRAP and Substance Evaluation
	Authorisation	<input type="checkbox"/> Candidate List
		<input type="checkbox"/> Annex XIV
	Restriction	<input type="checkbox"/> Annex XVII <sup>4</sup>
Harmonised C&L	<input type="checkbox"/> Annex VI (CLP) (see section 3.1)	
Processes under other EU legislation	<input type="checkbox"/> Plant Protection Products Regulation Regulation (EC) No 1107/2009	
	<input type="checkbox"/> Biocidal Product Regulation Regulation (EU) 528/2012 and amendments	
Previous legislation	<input type="checkbox"/> Dangerous substances Directive Directive 67/548/EEC (NONS)	
	<input type="checkbox"/> Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)	
(UNEP) Stockholm convention (POPs) (Protocol)	<input type="checkbox"/> Assessment	
	<input type="checkbox"/> In relevant Annex	
Other processes / EU legislation	<input type="checkbox"/> Other (provide further details below)	

<sup>4</sup> Please specify the relevant entry.



Further details	<p>Regulated in cosmetic products as described in Annex VI of the Regulation (EC) No 1223/2009 on Cosmetic Products.</p> <p>A compliance check is in progress for the substance.</p>
--------------------	--

### **3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)**

#### **3.1 Classification**

##### **3.1.1 Harmonised Classification in Annex VI of the CLP**

There is no harmonised Classification for the substance in Annex VI.

##### **3.1.2 Self classification**

- In the registration:

Not classified

- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Skin Irrit. 2	H315
Aquatic Chronic 4	H413
Eye Irrit. 2	H319

##### **3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP**

No Proposal for Harmonised Classification and Labeling has been submitted to the Registry of Intentions.

## 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES<sup>5</sup>

### 4.1 Tonnage and registration status

**Table: Tonnage and registration status**

<b>From ECHA dissemination site *</b>		
<input checked="" type="checkbox"/> Full registration(s) (Art. 10)	<input type="checkbox"/> Intermediate registration(s) (Art. 17 and/or 18)	
Tonnage band (as per dissemination site)		
<input type="checkbox"/> 1 - 10 tpa	<input type="checkbox"/> 10 - 100 tpa	<input type="checkbox"/> 100 - 1000 tpa
<input checked="" type="checkbox"/> 1000 - 10,000 tpa	<input type="checkbox"/> 10,000 - 100,000 tpa	<input type="checkbox"/> 100,000 - 1,000,000 tpa
<input type="checkbox"/> 1,000,000 - 10,000,000 tpa	<input type="checkbox"/> 10,000,000 - 100,000,000 tpa	<input type="checkbox"/> > 100,000,000 tpa
<input type="checkbox"/> <1 . . . . . >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa)		<input type="checkbox"/> Confidential

\*the total tonnage band has been calculated by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11):

[https://echa.europa.eu/documents/10162/22308542/manual\\_dissemination\\_en.pdf/7e0b87c2-2681-4380-8389-cd655569d9f0](https://echa.europa.eu/documents/10162/22308542/manual_dissemination_en.pdf/7e0b87c2-2681-4380-8389-cd655569d9f0)

### 4.2 Overview of uses

Ethyl hexyl salicylate is used as UVA and UVB absorber in cosmetics (e.g. sun screens) and personal care products.

#### Part 1:

<input checked="" type="checkbox"/> Manufacture	<input checked="" type="checkbox"/> Formulation	<input checked="" type="checkbox"/> Industrial use	<input checked="" type="checkbox"/> Professional use	<input checked="" type="checkbox"/> Consumer use	<input type="checkbox"/> Article service life	<input checked="" type="checkbox"/> Closed system
---	---	--	--	--	---	---

#### Part 3: There is high potential for exposure of

<input type="checkbox"/> Humans	<input checked="" type="checkbox"/> Environment
---------------------------------	---

<sup>5</sup> Dissemination site accessed on 20 July 2017

## 5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

### 5.1. Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)  
 Article 45(5) (Member State priority)

### 5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

- Fulfils criteria as CMR/ Suspected CMR  
 Fulfils criteria as Sensitiser/ Suspected sensitiser  
 Fulfils criteria as potential endocrine disrupter  
 Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB  
 Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)  
 Fulfils exposure criteria  
 Fulfils MS's (national) priorities

### 5.3. Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns		
CMR <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	Suspected CMR <sup>1</sup> <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	<input checked="" type="checkbox"/> Potential endocrine disruptor
<input type="checkbox"/> Sensitiser	<input type="checkbox"/> Suspected Sensitiser <sup>6</sup>	
<input type="checkbox"/> PBT/vPvB	<input type="checkbox"/> Suspected PBT/vPvB <sup>1</sup>	<input type="checkbox"/> Other (please specify below)
Exposure/risk based concerns		
<input type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Exposure of sensitive populations
<input type="checkbox"/> Exposure of environment	<input type="checkbox"/> Exposure of workers	<input type="checkbox"/> Cumulative exposure
<input type="checkbox"/> High RCR	<input type="checkbox"/> High (aggregated) tonnage	<input type="checkbox"/> Other (please specify below)

<sup>6</sup> CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)  
Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)  
Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

*In vitro* studies are available that show weak estrogenic effects (Morohoshi et al. 2005; Miller et al. 2001). Also weak anti-estrogenic and androgen effects were seen (Kunz and Fent 2006). Most pronounced were anti-androgen effects also seen by Kunz and Fent (2006) in an *in vitro* assay.

Ethyl hexyl salicylate is structurally related to homosalate and benzyl salicylate, another UV absorber used in cosmetics which also shows *in vitro* endocrine properties.

As available data on registered uses suggest that there is relevant exposure of the environment to the substance, further tests may be required to clarify the concern of endocrine disruption to the environment.

#### 5.4. Preliminary indication of information that may need to be requested to clarify the concern

<input type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on physico-chemical properties
<input type="checkbox"/> Information on fate and behaviour	<input type="checkbox"/> Information on exposure
<input type="checkbox"/> Information on ecotoxicological properties	<input type="checkbox"/> Information on uses
<input checked="" type="checkbox"/> Information ED potential	<input type="checkbox"/> Other (provide further details below)
<p>Based on the preliminary evaluation of the data related to endocrine disrupting properties of ethyl hexyl salicylate, <i>in vitro</i> studies and chronic studies using aquatic vertebrate (e.g. fish sexual development test) could be requested to clarify the concern on the estrogenic effects in the environment.</p> <p>Additionally, a detailed evaluation of the available data may lead to further information requirements.</p>	

#### 5.5. Potential follow-up and link to risk management

<input type="checkbox"/> Harmonised C&L	<input checked="" type="checkbox"/> Restriction	<input checked="" type="checkbox"/> Authorisation	<input checked="" type="checkbox"/> Other (provide further details)
<p>Depending on the outcome of the substance evaluation, an analysis of Risk Management Options shall be carried out to identify appropriate risk management measures.</p> <p>If the substance is to be considered an Endocrine Disruptor according to WHO/IPCS definition, SVHC identification and candidate listing might be the first steps that will be further analysed in a risk management option analysis.</p>			

## References

Kunz PY., Fent K. 2006: Multiple hormonal activities of UV filters and comparison of in vivo and in vitro estrogenic activity of ethyl-4-aminobenzoate in fish. *Aquat Toxicol* 79(4), 305-324.

Morohoshi K., Yamamoto H., Kamata R., Shiraishi F., Koda T., Morita M. 2005: Estrogenic activity of 37 components of commercial sunscreen lotions evaluated by in vitro assays. *Toxicol In Vitro* 19(4), 457-469.

Miller D., Wheals bb., Beresford N., Sumpter JP. 2001: Estrogenic Activity of Phenolic Additives Determined By an In Vitro Yeast Bioassay. *Environ Health Perspec* 109 (2), 133-138.